The Cystic Fibrosis Foundation is investing up to $3 million in ViaNautis for preclinical research into its non-viral, genetic therapy delivery mechanism called polyNaut^®.  ViaNautis aims for its delivery mechanism to reach the targeted cells in the CF lungs and carry large genetic therapy payloads — two major challenges in delivering a CF genetic therapy. This approach may also allow for redosing of the genetic therapy, a useful option if the therapy’s effects are not permanent.

Delivering genetic therapies in CF is challenging because of the body’s natural defense mechanisms, including physical barriers in the lungs. In order to accelerate the development of a treatment for all people with CF, the Foundation is committed to addressing this challenge by funding a variety of delivery approaches, including viral and non-viral delivery platforms. 

This investment is part of the Foundation’s $500 million Path to a Cure, an ambitious research initiative to accelerate treatments for everyone with CF and ultimately deliver a cure.

To find out more about ongoing clinical trials of CF genetic therapies, you can visit the new genetic therapies section of the Clinical Trial Finder.